Skip to main content
SpringerLink
Log in

Phase II Trial of Aminocamptothecin (9-AC/DMA) in Patients with Advanced Squamous Cell Head and Neck Cancer

  • Published:
Investigational New Drugs Aims and scope Submit manuscript

Abstract

Fourteen patients with squamous cell carcinoma of the head and neck received 9-AC/DMA infusions of 850 mg/M2/day over 72 hours. Eligibility criteria included good performance status, advanced disease incurable by conventional means, no prior treatment of metastatic disease, and measurable lesions for objective response assessment. The infusions wererepeated at 21 day intervals until progression or prohibitive toxicity occurred.A median of 3 cycles (range 1–7) was given. No objective responses wereobserved. Median survival of the group was 6 months. Toxicity was hematologicwhich was modest and promptly reversible. 9-AC/DMA is inactive against this tumortype at the dose and schedule employed in this study.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Hertzberg RP, Caranfa MJ, Hecht SM: On the mechanism of topoisomerase-I inhibition by camptothecin: evidence for binding to an enzyme-DNA complex. Biochem 28 (11): 4629–4638, 1989

    Google Scholar 

  2. Bendixen C, Thomsen B, Aisner J, Westergaard O: Camptothecin-stabilized topoisomerase I-DNA adducts cause premature termination of transcription. Biochem 29 (23): 5613–5619, 1990

    Google Scholar 

  3. Giovanella BC, Stehlin JS, Wall ME, Wani MC, Nicholas AW, Lu LF, Silber R, Potmesil M: DNA topoisomerase I-targeted chemotherapy of human colon cancer in xenografts. Science 246 (4933): 1046–1048, 1989

    Google Scholar 

  4. Rougier P, Bugat R, Douillard JY, Culine S, Sue E, Brunet P, Becouarn Y, Ychou M, Marty M, Extra JM, Bonneterre J, Adenis A, Seitz JF, Ganer G, Namer M, Conroy T, Negrier S, Merrouche Y, Burki F, Mousseau M, Herait P, Mahjoubi M: Phase II study of irinotecan in the treatment of advanced colorectal cancer in chemotherapy-naive patients and patients treated with flourouracil-based chemotherapy. J Clin Oncol 15: 251–260, 1997

    Google Scholar 

  5. Fuktioka M, Nitani H, Suzuki A, Motomiya M, Hasegawa K, Nishiwaki Y, Kuriyama T, Ariyoshi Y, Negoro S, Masuda N: A phase II study of CPT11, a new derivative of camptothecin, for previously untreated non-small cell lung cancer. J Clin Oncol 10 (1): 16–20, 1992

    Google Scholar 

  6. Masuda N, Fukuoka M, Kudoh S, Matsui K, Kusunoki Y, Takada M, Nakagawa K, Hirashima T, Tsukada H, Yana T: Phase I study of irinotecan and cisplatin with granulocyte colony-stimulating factor support for advanced non-small cell lung cancer. J Clin Oncol 12 (1): 90–96, 1994

    Google Scholar 

  7. Perez-Soler R, Fossella FV, Glisson BS, Lee JS, Murphy WK, Shin DM, Kemp BL, Lee JJ, Kane J, Robinson RA, Lippman SM, Kurie JM, Huber MH, Raber MN, Hong WK: Phase II study of topotecan in patients with advanced non-small cell lung cancer previously untreated with chemotherapy. J Clin Oncol 14 (2): 503–513, 1996

    Google Scholar 

  8. Lynch TJ, Kalish L, Strauss G, Elias A, Skarin A, Shulman LN, Posner M, Frei E III: Phase II study of topotecan in metastatic non-small cell lung cancer. J Clin Oncol 12 (2): 347–352, 1994

    Google Scholar 

  9. Robert F, Soong SJ, Wheeler RH: A phase II study of topotecan in patients with recurrent head and neck cancer. Identification of an active new agent. Am J Clin Oncol 20 (3): 298–302, 1997

    Google Scholar 

  10. Smith RE, Lew D, Rodriguez GI, Taylor SA, Schuller D, Ensley H: Evaluation of topotecan in patients with recurrent or metastatic squamous cell carcinoma of the head and neck. A phase II Southwest Oncology Group study. J Clin Oncol 14(4): 403–407, 1996

    Google Scholar 

  11. Vokes EE, Ansari RH, Masters GA, Hoffman PC, Klepsch A, Ratain MJ, Sciortino DF, Lad TE, Krauss S, Fishkin PAS, Golomb HM: A phase II study of 9-aminocamptothecin in advanced non-small cell lung cancer. Ann Oncol 9: 1085–1090, 1998

    Google Scholar 

  12. Dahut BC, Brillhart N, Takimoto C, Allegra C, Hamilton JM, Sorenson JM, Arbuck SM, Chen A, Grem J: A phase I trial of 9-aminocamptothecin (9-AC/DMA) in adult patients with solid tumors. Proc Am Soc Clin Oncol 13: 138, 1994

    Google Scholar 

  13. Gehan EA: The determination of the number of patients required in a preliminary and follow-up trial of a new chemotherapeutic agent. J Chronic Dis 13: 346–353, 1961

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. West Side VA Medical Center, University of Illinois, Chicago, USA

    Thomas Lad & Fred Rosen

  2. Fort Wayne Medical Center, USA

    David Sciortino

  3. Weiss Memorial Hospital, USA

    Bruce Brockstein

  4. University of Chicago Cancer Research Center, University of Chicago, Phase II Network, USA

    Bruce Brockstein, Rose Arietta & Everett Vokes

  5. Ohio State University, USA

    J. Philip Keubler

Authors
  1. Thomas Lad
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Fred Rosen
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. David Sciortino
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Bruce Brockstein
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. J. Philip Keubler
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Rose Arietta
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Everett Vokes
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Lad, T., Rosen, F., Sciortino, D. et al. Phase II Trial of Aminocamptothecin (9-AC/DMA) in Patients with Advanced Squamous Cell Head and Neck Cancer. Invest New Drugs 18, 261–263 (2000). https://doi.org/10.1023/A:1006481924287

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1023/A:1006481924287

Search

Navigation